Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study

Basic Details
Date
Tuesday, June 7, 2016
Type
Publication
Medical Product
antihyperglycemic drug
insulin
pioglitazone
saxagliptin
sitagliptin
sulfonylurea
Health Outcome(s)
heart failure
Description

Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents. Objective: To examine the associations of hHF with saxagliptin and sitagliptin.

Materials

Ann Intern Med; Volume 164, Issue 11, Pages 705-714, DOI: 10.7326/M15-2568

Related Assessment(s)
Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart Failure
A Protocol for Active Surveillance of Acute Myocardial Infarction in Association with the use of a New Antidiabetic Pharmaceutical Agent
Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study
Sentinel Initiative Public Workshop - Ninth Annual
Mini-Sentinel Drug Assessment: Onglyza (Saxagliptin) and Januvia (Sitagliptin) & Hospitalized Heart Failure and Acute Myocardial Infarction (AMI)
Author(s)

Darren Toh ScD; Christian Hampp PhD; Marsha E. Reichman PhD; David J. Graham MD, MPH; Suchitra Balakrishnan; Frank Pucino; Jack Hamilton; Samuel Lendle; Aarthi Iyer MPH; Malcolm Rucker MS; Madelyn Pimentel BA; Neesha Nathwani; Marie R. Griffin MD, MPH; Nancy J. Brown; Bruce H. Fireman MA 

Corresponding Author

S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215. Email: darren_toh@harvardpilgrim.org

Scroll to Top